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Role of iron deficiency,  
Inflammation, obesity and DN 

What is the dilemma for Hb correction? 
HRQOL      CV Risk (?) 
























Worse effect of ESA high dosage  
and  ESA hyporesponsiveness 
Testosterone deficiency 
NDT 2011 Carrero et al : hypogonadism as a cause  
of anemia and ESA resistance in men with CKD 




1g IV Fer 2X500 vs IS 10X100 mg 
Superparamagnetic  
iron oxide coated  
with CH shell 
Bowry S. and Gatti E., Blood Purification, 2011, 32, 210-219.  
Bowry S. and Gatti E., Blood Purification, 2011, 32, 210-219.  
CJASN 2011; 6 
60000 u IV 
EPO alpha 
Single high dose Epoietin bêta after reperfusion in 
STEMI (Prunier et al Am H J 2012) (EPOMI study) 
• 110 patients 
• 1000 u/Kg IV EPOETIN beta immediately after 
reperfusion 
• Cardiac magnetic resonance 
• Transient favorable effects on LV volume (at 5d) 
• No reduction in infact size at 3 months 
EPO: Good or Bad for Cancer? 
• EPO binds its receptor EPO R                                
surface of RBC progenitors                                  
in the bone marrow. 
• EPO binds EPO R expressed                               
on the surface of cancer cells                                 
and may elicit tumor growth. 
- Moreover, increase risk of                                 
venous thromboembolism                                     
(Bennett et al JAMA 2008) Fig: Brower Nat Med 2003 
ESA and cancer risk? 
• 2009: (Cochrane database syst rev) ESA treatment in cancer 
patients increased on study mortality and worsened overall 
survival. 
• This was less pronounced for patients undergoing chemotherapy. 
• There is also  a risk for venous thromboembolic events, 
particularly when ESA are used off label. 
• 2012: (Br J Cancer) ESAs may have little effect on disease 
progression in chemotherapy patients. Preclinical data indicate  
an effect of ESAs on tumour growth is not strongly supported. 
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So, in CKD, there is a problem  
of abnormal oxygen sensing 
Conclusions 
• Partial correction (Hb in the range of 10-11.5 g/dL) of 
CKD-related anemia appears a safer strategy during the 
last 5y. So recommendation is to start ESA only when 
Hb <10 and to avoid too high ESA dose (CE DOSE 
study ongoing in HD)! 
• Identify resistant patients and try to improve it. 
• Importance of adequate iron management and of 
hepcidin role in the all-mortality risk in CKD. 
• Newer strategies for correcting anemia are currently 
explored.   

